Status:
ENROLLING_BY_INVITATION
Exparel vs Block for ACL Reconstruction
Lead Sponsor:
Rothman Institute Orthopaedics
Conditions:
ACL
Postoperative Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Adminis...
Eligibility Criteria
Inclusion
- Paticipants with ACL rupture amenable to reconstruction with BTB autograft identified in clinic by one of 4 different surgeons
- Primary ACL Reconstruction with Autograft +/- Partial meniscectomy +/- Lateral extra-articular tenodesis
- Age 18 and older
- English speaking
- Ability to complete surveys by phone or in person
- Ability to provide informed consent
Exclusion
- Revision cases
- Multi-ligamentous knee injuries
- Cartilage or meniscal procedures that prevent adherence to immediate weight bearing and range of motion rehab protocol
- ACL reconstruction utilizing non-bone-patellar tendon-bone autografts
- Allergies to study medications
- Non-English speakers
- Known alcohol or narcotic abuse history
- Existing contract with a pain specialist due to underlying preoperative pain syndrome
- Preoperative opioid use within the 3 months prior to surgery
Key Trial Info
Start Date :
August 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2024
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT06006624
Start Date
August 21 2023
End Date
October 30 2024
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States, 19107